Literature DB >> 7465462

Prevention of coronary heart disease: the role of essential fatty acids.

H M Sinclair.   

Abstract

There are 2 classes of essential fatty acids (EFA), the linoleic (n-6) and linolenic (n-3). They are required for the glycerophosphatides (phospholipids) of cellular membranes; the transport and oxidation of cholesterol; the formation of prostaglandins. In deficiency of EFA, cellular membranes are imperfectly formed which causes increased susceptibility to various insults and increased permeability. Low-density lipoproteins (LDL) transport cholesterol mainly as cholesteryl linoleate and supply EFA to tissue. A relative deficiency of EFA (i.e. a high ratio in the body of non-EFA such as long-chain saturated fatty acids to EFA) causes an increase in plasma cholesterol. EFAs cause decreased aggregation of platelets. Atherosclerosis is not caused by increased aggregation of platelets, and can be prevalent in a population in which coronary thrombosis is rare.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7465462      PMCID: PMC2425959          DOI: 10.1136/pgmj.56.658.579

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  19 in total

1.  THE ENZYMATIC FORMATION OF PROSTAGLANDIN E2 FROM ARACHIDONIC ACID PROSTAGLANDINS AND RELATED FACTORS 32.

Authors:  S BERGSTROEM; H DANIELSSON; B SAMUELSSON
Journal:  Biochim Biophys Acta       Date:  1964-07-15

2.  ENZYMATIC CONVERSION OF ALL-CIS-POLYUNSATURATED FATTY ACIDS INTO PROSTAGLANDINS.

Authors:  R K BEERTHUIS; D H NUGTEREN; H VONKEMAN
Journal:  Nature       Date:  1964-08-22       Impact factor: 49.962

3.  The synthesis of phospholipids in human atheromatous lesions.

Authors:  D B ZILVERSMIT; E L McCANDLESS; P H JORDAN; W S HENLY; R F ACKERMAN
Journal:  Circulation       Date:  1961-03       Impact factor: 29.690

4.  The effect of fatty acids on the formation of thrombi.

Authors:  W E CONNOR; J C POOLE
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1961-01

5.  Arteriosclerosis in African populations.

Authors:  J F BROCK; B BRONTE-STEWART
Journal:  Minn Med       Date:  1955-12

6.  Deficiency of essential fatty acids and atherosclerosis, etcetera.

Authors:  H M SINCLAIR
Journal:  Lancet       Date:  1956-04-07       Impact factor: 79.321

7.  Thromboxanes: selective biosynthesis and distinct biological properties.

Authors:  P Needleman; M Minkes; A Raz
Journal:  Science       Date:  1976-07-09       Impact factor: 47.728

8.  Relationship between chemical structure and platelet-aggregation activity of prostaglandins.

Authors:  J Kloeze
Journal:  Biochim Biophys Acta       Date:  1969-10-28

9.  Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation.

Authors:  R J Gryglewski; J A Salmon; F B Ubatuba; B C Weatherly; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1979-09

10.  Haemostatic function and platelet polyunsaturated fatty acids in Eskimos.

Authors:  J Dyerberg; H O Bang
Journal:  Lancet       Date:  1979-09-01       Impact factor: 79.321

View more
  4 in total

1.  Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years.

Authors:  R Saynor; T Gillott
Journal:  Lipids       Date:  1992-07       Impact factor: 1.880

2.  Eicosapentaenoic acid inhibits the release of 14C-prostacyclin from a perfused tissue after incorporation of 14C-prostaglandin precursors.

Authors:  H Juan; W Sametz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

3.  How do polyunsaturated fatty acids lower plasma cholesterol levels?

Authors:  D F Horrobin; M S Manku
Journal:  Lipids       Date:  1983-08       Impact factor: 1.880

4.  Effect of sleep deprivation on cholesterol metabolism and triglyceridaemia in male volunteers.

Authors:  K Vondra; V Brodan; M Dobiásová; V Vítek; J Kopecká
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1986
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.